Spinnaker Trust acquired a new stake in shares of C.R. Bard, Inc. (NYSE:BCR) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 787 shares of the medical instruments supplier’s stock, valued at approximately $249,000.
A number of other large investors have also bought and sold shares of the stock. Cribstone Capital Management LLC purchased a new stake in shares of C.R. Bard during the first quarter valued at about $130,000. Contravisory Investment Management Inc. raised its stake in shares of C.R. Bard by 349.2% in the first quarter. Contravisory Investment Management Inc. now owns 548 shares of the medical instruments supplier’s stock valued at $136,000 after buying an additional 426 shares during the period. Whittier Trust Co. raised its stake in shares of C.R. Bard by 7.7% in the first quarter. Whittier Trust Co. now owns 591 shares of the medical instruments supplier’s stock valued at $147,000 after buying an additional 42 shares during the period. ClariVest Asset Management LLC bought a new position in C.R. Bard during the first quarter valued at approximately $148,000. Finally, SRS Capital Advisors Inc. increased its position in C.R. Bard by 0.7% in the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock valued at $148,000 after buying an additional 4 shares in the last quarter. 85.32% of the stock is owned by institutional investors.
C.R. Bard, Inc. (BCR) traded up 0.19% during trading on Friday, reaching $319.75. The company had a trading volume of 330,226 shares. The stock has a market capitalization of $23.24 billion, a P/E ratio of 41.98 and a beta of 0.59. The stock has a 50 day moving average of $319.00 and a 200-day moving average of $283.44. C.R. Bard, Inc. has a 12-month low of $203.63 and a 12-month high of $323.27.
C.R. Bard (NYSE:BCR) last posted its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.84 by $0.08. The firm had revenue of $979.70 million for the quarter, compared to analyst estimates of $976.53 million. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. C.R. Bard’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.54 earnings per share. On average, analysts forecast that C.R. Bard, Inc. will post $11.84 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Friday, August 4th. Investors of record on Monday, July 24th were given a dividend of $0.26 per share. The ex-dividend date of this dividend was Thursday, July 20th. This represents a $1.04 dividend on an annualized basis and a yield of 0.33%. C.R. Bard’s payout ratio is presently 13.67%.
ILLEGAL ACTIVITY WARNING: “787 Shares in C.R. Bard, Inc. (BCR) Acquired by Spinnaker Trust” was posted by BNB Daily and is the sole property of of BNB Daily. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.baseball-news-blog.com/2017/08/14/spinnaker-trust-acquires-shares-of-787-c-r-bard-inc-bcr-updated.html.
BCR has been the topic of several analyst reports. Zacks Investment Research upgraded C.R. Bard from a “hold” rating to a “buy” rating and set a $342.00 price objective on the stock in a report on Thursday, May 11th. BidaskClub upgraded C.R. Bard from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 8th. Morgan Stanley downgraded C.R. Bard from an “overweight” rating to an “equal weight” rating in a report on Monday, April 24th. Jefferies Group LLC boosted their price target on C.R. Bard from $237.00 to $317.00 and gave the company a “hold” rating in a report on Monday, April 24th. Finally, Raymond James Financial, Inc. downgraded C.R. Bard from a “strong-buy” rating to a “mkt perform” rating in a report on Wednesday, April 26th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $285.67.
In related news, insider John P. Groetelaars sold 23,687 shares of the business’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the transaction, the insider now directly owns 31,445 shares in the company, valued at $10,022,464.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.80% of the company’s stock.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.